CTOs on the Move

Family Care Center

www.fcsprings.com

 
Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fcsprings.com
  • 1330, Quail Lake Loop
    Colorado Springs, CO USA 80906
  • Phone: 719.540.2146

Executives

Name Title Contact Details

Similar Companies

Minnetronix Medical

Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world.

Bioxene

Bioxene is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stat-Tech Services

Stat-Tech Services is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.